



Investor Service Announcement no. 2/2009

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, March 23, 2009

LifeCycle Pharma A/S to Present at the 14th Annual Carnegie Nordic Health Care Seminar in Stockholm on March 25-26, 2009.

LifeCycle Pharma A/S (OMX: LCP) today announced that its CEO, Mr. Jim New, is scheduled to present a company update at the 14th Annual Carnegie Nordic Health Care Seminar in Stockholm at 17:00 (CET). The two-day conference for the pharmaceutical industry is being held March 25th to 26th, 2009, in the Carnegie office in Stockholm.

For more information, please contact:

Dr. Jim New

President & Chief Executive Officer

Phone: + 45 7033 3300

Email: JSN@lcpharma.com

or

Peter Schøtt Knudsen

Head of Investor Relations

Phone: + 45 2055 3817

Email: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose[®], can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide[™], currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.